Symbols

APGN(Delisted)

Apexigen·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About APGN

Apexigen, Inc.

A clinical-stage biopharmaceutical company that developing a new generation of antibody therapeutics for oncology to combat and eradicate cancer

Industry

Established Date

Listing Date

02/22/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.apexigen.com

Security Type

Common stock

Office address

75 Shoreway Road, Suite C, San Carlos, CA 94070

Business

Introduction

Apexigen, Inc., was incorporated in Delaware in 2010. The company is a clinical-stage biopharmaceutical company focused on the development of innovative antibody therapies for the treatment of cancer, with an emphasis on immuno-oncology. The company has established a diversified pipeline of wholly-owned and cooperative assets using its proprietary APXiMAB antibody discovery platform. The company's main asset, sotigalimab, is a potential best-in-class and first-in-class CD40 agonist with unique epitope specificity and Fc receptor involvement for optimal therapeutic outcomes.

Company Financials

EPS

APGN has released its 2023 Q2 earnings. EPS was reported at -0.24, versus the expected 0, missing expectations. The chart below visualizes how APGN has performed over recent quarters, highlighting trends in earnings surprises.